P376: VENO-OCCLUSIVE DISEASE RISK AND OTHER OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION

• Marcos de Lima,
• Partow Kebriaei,
• Francesco Lanza,
• Christina Cho,
• Gizelle Popradi,
• Manmeet Kaur,
• Mei-Jie Zhang,
• Fan Zhang,
• Saara Tikka,
• Erik Vandendries,
• Kofi Asomaning,
• Stephanie Dorman,
• Matthias Stelljes,
• David Marks,
• Wael Saber

Affiliations

Marcos de Lima

1 Ohio State University, Blood and Marrow and Cellular Therapy Program, Columbus, United States

Partow Kebriaei

2 MD Anderson Cancer Center, Houston, United States

Francesco Lanza

3 Ospedale di Ravenna, Ravenna, Italy

Christina Cho

4 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, United States

Gizelle Popradi

5 McGill University Health Centre, Montreal, Canada

Manmeet Kaur

6 Center for International Blood and Marrow Transplant Research, MIlwaukee, United States

Mei-Jie Zhang

6 Center for International Blood and Marrow Transplant Research, MIlwaukee, United States

Fan Zhang

7 Pfizer Inc, Shanghai, China

Saara Tikka

8 Pfizer Oy, Helsinki, Finland

Erik Vandendries

9 Pfizer Inc, Cambridge, United States

Kofi Asomaning

9 Pfizer Inc, Cambridge, United States

Stephanie Dorman

10 Pfizer Inc, Ontario, Canada

Matthias Stelljes

11 Universitätsklinikum Münster, Münster, Germany

David Marks

12 University Hospitals Bristol NHS Trust, Bristol, United Kingdom

Wael Saber

6 Center for International Blood and Marrow Transplant Research, MIlwaukee, United States